# Audit cards (plain-language form)

Rendered by the program from each judge's extraction. Nothing here has been checked by a person yet.

## vitd: Does vitamin D supplementation reduce the risk of acute respiratory infections in adults?

### anthropic/claude-haiku-4.5

**Conclusion.** Vitamin D supplementation does not consistently reduce the risk of acute respiratory infections in adults, although a possible small benefit may remain for people with severe vitamin D deficiency or for specific dosing regimens.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 1 study is wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 1 study is wrong.

**Checklist to reach the target** (4 checks; all must be confirmed; single points of failure first)
1. U1 [single point of failure]: Meta-analyses and systematic reviews of RCTs provide valid evidence for population-level preventive effects  *Look in:* refs 1, 2, 3, 4.  *If false:* no support remains; stop.
2. C2: The baseline vitamin D concentrations and deficiency thresholds in the trials match clinically relevant definitions of severe deficiency  *Look in:* refs 1, 3.  *If false:* at best the conclusion holds only if every study it uses is correct.
3. C3: The dosing regimens tested (including 400-1,200 IU daily) represent the relevant supplementation strategies for clinical practice  *Look in:* refs 2.  *If false:* at best the conclusion holds even if any 1 study is wrong.
4. C4: Seasonal variation in benefit (spring, autumn, winter) is generalizable across different geographic and climate contexts  *Look in:* refs 2.  *If false:* at best the conclusion holds even if any 1 study is wrong.
*If all 4 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: Martineau 2017 individual-participant-data meta-analysis of 25 RCTs (ref 1)
- S2: 2024 systematic review and meta-analysis of 43 RCTs (ref 2)
- S3: 2024 systematic review focused on ARI prevention (ref 3)
- S4: 2024 aggregate-data meta-analysis of 46 RCTs (ref 4)

**Smallest ways the conclusion can lose all support** (29 in total): U1 false; C2 false and S2 wrong; S1, S2 wrong; C1, C3 false and S3 wrong; C1, C4 false and S3 wrong; C1 false and S2, S3 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2; a person must accept them.
- References whose study could not be identified: none.

### openai/gpt-4.1

**Conclusion.** Vitamin D supplementation does not consistently reduce the risk of acute respiratory infections (ARIs) in adults, although a possible small benefit remains for people with severe vitamin D deficiency or for specific dosing regimens.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED; the target cannot be reached.**
- If every assumption below holds, the conclusion holds only if every study it uses is correct.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds only if every study it uses is correct.

Single points of failure: C1: The populations, dosing regimens, and ARI definitions in the cited meta-analyses are sufficiently similar to the general adult population and supplementation practices addressed in the conclusion.; U1: The meta-analyses included all relevant and high-quality randomized controlled trials up to their respective dates.
**Checklist.** None: even if every assumption is confirmed, the target is out of reach. More independent evidence is needed, or the conclusion must be narrowed.

**Studies behind the references**
- S1: Martineau 2017 individual participant data meta-analysis (ref 1)
- S2: 2024 systematic review and meta-analysis (Springer, unknown authors) (ref 2)
- S3: 2024 systematic review and meta-analysis (PMC, unknown authors) (ref 3)
- S4: 2024 aggregate data meta-analysis (medRxiv, unknown authors) (ref 4)

**Smallest ways the conclusion can lose all support** (9 in total): C1 false; U1 false; S2 wrong; C2, C4 false; C2 false and S1 wrong; C4 false and S4 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1; a person must accept them.
- References whose study could not be identified: none.

### qwen/qwen3-235b-a22b-2507

**Conclusion.** Vitamin D supplementation does not consistently reduce the risk of acute respiratory infections (ARIs) in adults, although a possible small benefit remains for people with severe vitamin D deficiency or for specific dosing regimens.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 3 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 3 studies are wrong.

**Checklist to reach the target** (6 checks; all must be confirmed; single points of failure first)
1. U1 [single point of failure]: The outcome of 'experiencing at least one ARI' is clinically meaningful and comparable across studies.  *Look in:* refs 1, 2, 3, 4.  *If false:* no support remains; stop.
2. C2: The dosing regimens studied (e.g., daily 400–1,200 IU) are representative of typical supplementation patterns in the target population.  *Look in:* refs 2.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
3. C3: The definition and measurement of acute respiratory infections are consistent across the included studies.  *Look in:* refs 2, 3, 4.  *If false:* at best the conclusion holds only if every study it uses is correct.
4. C5: The statistical methods used in the meta-analyses appropriately account for heterogeneity and risk of bias across trials.  *Look in:* refs 3, 4.  *If false:* at best the conclusion holds even if any 1 study is wrong.
5. C6: The newer large trials included in the 2024 reviews are methodologically sound and representative of the population of interest.  *Look in:* refs 2, 4.  *If false:* at best the conclusion holds even if any 1 study is wrong.
6. U2: The biological mechanism by which vitamin D could influence ARI risk operates similarly across different populations and settings.  *Look in:* refs 2, 3, 4.  *If false:* at best the conclusion holds only if every study it uses is correct.
*If all 6 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: Martineau 2017 meta-analysis (ref 1)
- S2: 2024 systematic review and meta-analysis (Springer) (ref 2)
- S3: 2024 systematic review and meta-analysis (PMC) (ref 3)
- S4: 2024 aggregate-data meta-analysis (medRxiv) (ref 4)

**Smallest ways the conclusion can lose all support** (34 in total): U1 false; C1, C3 false; C1, U2 false; C3, C4 false; C3 false and S1 wrong; C4, U2 false ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2; a person must accept them.
- References whose study could not be identified: none.

## creatine: Is long-term creatine supplementation safe for kidney function in healthy adults?

### anthropic/claude-haiku-4.5

**Conclusion.** Long-term creatine supplementation appears safe for kidney function in healthy adults when used at standard doses, although it can modestly raise blood creatinine without indicating actual kidney injury.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 3 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 3 studies are wrong.

**Checklist to reach the target** (4 checks; all must be confirmed; single points of failure first)
1. C1: The user is a healthy adult with no pre-existing kidney disease  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* at best the conclusion holds only if every study it uses is correct.
2. C2: Creatine is used at standard doses, typically 3–5 g/day  *Look in:* refs 1, 2, 3, 5.  *If false:* at best the conclusion holds even if any 1 study is wrong.
3. C7: The study populations in references 1-5 are representative of the healthy adult population to which the conclusion applies  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* at best the conclusion holds only if every study it uses is correct.
4. U1: Absence of evidence of kidney harm in the studies reviewed constitutes sufficient evidence of safety  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* at best the conclusion holds only if every study it uses is correct.
*If all 4 are confirmed:* the conclusion holds even if any 3 studies are wrong.

**Studies behind the references**
- S1: Antonio et al. 2019 systematic review and meta-analysis (ref 1)
- S2: 2025 systematic review and meta-analysis on creatine and kidney function (ref 2)
- S3: 2023 review on creatine supplementation and kidney dysfunction (ref 3)
- S4: 2025 safety review of creatine supplementation (ref 4)
- S5: Kreider et al. 2017 International Society of Sports Nutrition position stand (ref 5)

**Smallest ways the conclusion can lose all support** (18 in total): C1, C6 false; C1, U2 false; C1 false and S3 wrong; C1 false and S2 wrong; C6, C7 false; C6, U1 false ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2; a person must accept them.
- References whose study could not be identified: none.

### openai/gpt-4.1

**Conclusion.** Long-term creatine supplementation appears safe for kidney function in healthy adults when used at standard doses.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 4 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 4 studies are wrong.

**Checklist to reach the target** (4 checks; all must be confirmed; single points of failure first)
1. C1 [single point of failure]: The populations, doses, and durations studied in the cited reviews and studies are representative of healthy adults using standard creatine supplementation protocols.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
2. C2 [single point of failure]: The absence of observed kidney dysfunction in the cited studies is sufficient to infer safety for kidney function in healthy adults at standard doses.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
3. C3 [single point of failure]: The increase in serum creatinine observed with creatine supplementation does not reflect actual kidney injury in healthy adults.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
4. C4 [single point of failure]: The findings from studies with durations up to 60 months can be generalized to 'long-term' use as referenced in the conclusion.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
*If all 4 are confirmed:* the conclusion holds even if any 4 studies are wrong.

**Studies behind the references**
- S1: Antonio 2019 systematic review and meta-analysis (ref 1)
- S2: 2025 systematic review and meta-analysis (unknown authors) (ref 2)
- S3: 2023 narrative review (unknown authors) (ref 3)
- S4: 2025 safety review (unknown authors) (ref 4)
- S5: Kreider 2017 ISSN position stand (ref 5)

**Smallest ways the conclusion can lose all support** (5 in total): C1 false; C2 false; C3 false; C4 false; S1, S2, S3, S4, S5 wrong

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: none; a person must accept them.
- References whose study could not be identified: none.

### qwen/qwen3-235b-a22b-2507

**Conclusion.** Long-term creatine supplementation appears safe for kidney function in healthy adults when used at standard doses, although it can modestly raise blood creatinine—a marker that may falsely suggest reduced kidney function without indicating actual kidney injury.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 4 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 4 studies are wrong.

**Checklist to reach the target** (3 checks; all must be confirmed; single points of failure first)
1. U1 [single point of failure]: Standard doses of creatine supplementation (e.g., 3–5 g/day) do not cause structural or functional kidney damage in healthy adults over the long term.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
2. C1: The populations studied in the Antonio 2019 meta-analysis are representative of healthy adults using standard-dose creatine supplementation.  *Look in:* refs 1.  *If false:* at best the conclusion holds even if any 3 studies are wrong.
3. C2: The populations studied in the 2025 meta-analysis are representative of healthy adults using standard-dose creatine supplementation.  *Look in:* refs 2, 3.  *If false:* at best the conclusion holds even if any 3 studies are wrong.
*If all 3 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: Antonio 2019 meta-analysis (ref 1)
- S2: 2025 meta-analysis (ref 2)
- S3: 2023 review (ref 3)
- S4: 2025 safety review (ref 4)
- S5: Kreider 2017 position stand (ref 5)

**Smallest ways the conclusion can lose all support** (33 in total): U1 false; C1, C2, C3, C4, C5 false; C1, C2, C3, C4 false and S5 wrong; C1, C2, C3, C5 false and S4 wrong; C1, C2, C3 false and S4, S5 wrong; C1, C2, C4, C5 false and S3 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2; a person must accept them.
- References whose study could not be identified: none.

## lfp: Do lithium iron phosphate (LFP) home storage batteries last more than 6000 full cycles?

### anthropic/claude-haiku-4.5

**Conclusion.** Some LFP home-storage batteries are specified to last more than 6,000 full-equivalent cycles, but this depends strongly on depth of discharge, temperature, charge rate, and the manufacturer's end-of-life definition.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 1 study is wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 1 study is wrong.

**Checklist to reach the target** (9 checks; all must be confirmed; single points of failure first)
1. C1: The Wilhelm et al. 2018 study's findings on commercial lithium-iron-phosphate/graphite cells' cycle stability up to 10,000 FECs apply to home-storage battery products  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds only if every study it uses is correct.
2. C2: The Wilhelm et al. 2018 estimate that a typical home-storage system operating for 20 years would experience about 6,000 FECs applies to the systems being evaluated  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds only if every study it uses is correct.
3. C3: The Omar et al. 2014 experimental findings on LFP battery cycle life at different depths of discharge, temperatures, and charging rates apply to commercial home-storage products  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds only if every study it uses is correct.
4. C4: Pylontech EVOLVE LFP's specification of more than 6,000 cycles at 90% depth of discharge and 25°C is accurate as stated in the datasheet  *Look in:* refs 3, 4, 5.  *If false:* at best the conclusion holds only if every study it uses is correct.
5. C5: GoodWe Lynx A G3's specification of more than 6,000 cycles at 70% remaining capacity end-of-life criterion is accurate as stated in the datasheet  *Look in:* refs 3, 4, 5.  *If false:* at best the conclusion holds only if every study it uses is correct.
6. C6: Deye SE-F12's specification of exactly 6,000 cycles is accurate as stated in the datasheet  *Look in:* refs 3, 4, 5.  *If false:* at best the conclusion holds only if every study it uses is correct.
7. C7: The tested cells in Omar et al. 2014 are representative of LFP chemistry used in commercial home-storage batteries  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds only if every study it uses is correct.
8. U1: The definition of 'full-equivalent cycle' used in the cited studies matches the definition used by the commercial manufacturers cited  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds only if every study it uses is correct.
9. U2: The end-of-life capacity thresholds (70%, 80%, 90%) used in different studies and products are comparable or their differences are accounted for in the comparison  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds only if every study it uses is correct.
*If all 9 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: Wilhelm et al. 2018 laboratory and modelling study (ref 1)
- S2: Omar et al. 2014 experimental study (ref 2)
- S3: Pylontech EVOLVE LFP product datasheet 2025 (ref 3)
- S4: GoodWe Lynx A G3 product datasheet 2026 (ref 4)
- S5: Deye SE-F12 product datasheet 2026 (ref 5)

**Smallest ways the conclusion can lose all support** (48 in total): C1, C4 false; C1, C5 false; C1, C6 false; C1 false and S5 wrong; C1 false and S4 wrong; C1 false and S3 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2; a person must accept them.
- References whose study could not be identified: none.

### openai/gpt-4.1

**Conclusion.** High-quality LFP home batteries can be rated above 6,000 full-equivalent cycles, and some independent evidence indicates that LFP cells can exceed this level; nevertheless, buyers should compare the complete warranty test conditions—not chemistry alone—including depth of discharge, temperature, power rate, usable capacity at end of warranty, and calendar-life limit.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 1 study is wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 1 study is wrong.

**Checklist to reach the target** (4 checks; all must be confirmed; single points of failure first)
1. C3 [single point of failure]: The definition of 'full-equivalent cycle' and end-of-life threshold used in the studies and datasheets matches the one in the report's conclusion.  *Look in:* refs 1, 2, 3, 4.  *If false:* no support remains; stop.
2. C4 [single point of failure]: The operating conditions (depth of discharge, temperature, charge rate) in the cited studies and datasheets are comparable to those in typical home battery use.  *Look in:* refs 1, 2, 3, 4.  *If false:* no support remains; stop.
3. C1: The laboratory-tested cells in Wilhelm 2018 and Omar 2014 are representative of commercial LFP home-storage batteries.  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds only if every study it uses is correct.
4. C2: The cycle-life specifications in the Pylontech, GoodWe, and Deye datasheets reflect actual product performance under typical home-storage conditions.  *Look in:* refs 3, 4.  *If false:* at best the conclusion holds only if every study it uses is correct.
*If all 4 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: Wilhelm 2018 laboratory and modeling study (ref 1)
- S2: Omar 2014 laboratory study (ref 2)
- S3: Pylontech EVOLVE LFP datasheet (ref 3)
- S4: GoodWe Lynx A G3 datasheet (ref 4)
- S5: Deye SE-F12 Battery datasheet (ref 5)

**Smallest ways the conclusion can lose all support** (11 in total): C3 false; C4 false; C1, C2 false; C1 false and S4 wrong; C1 false and S3 wrong; C2 false and S2 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: none; a person must accept them.
- References whose study could not be identified: none.

### qwen/qwen3-235b-a22b-2507

**Conclusion.** Yes, high-quality LFP home batteries can be rated above 6,000 full-equivalent cycles, and some independent evidence indicates that LFP cells can exceed this level; nevertheless, buyers should compare the complete warranty test conditions—not chemistry alone—including depth of discharge, temperature, power rate, usable capacity at end of warranty, and calendar-life limit.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 2 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 2 studies are wrong.

**Checklist to reach the target** (8 checks; all must be confirmed; single points of failure first)
1. U3 [single point of failure]: The definition of 'home-storage battery' in the studies and datasheets matches the one in the conclusion.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
2. C1: The tested LFP cells in Wilhelm et al. 2018 are representative of those used in home-storage batteries.  *Look in:* refs 1.  *If false:* at best the conclusion holds even if any 1 study is wrong.
3. C2: The operating conditions (depth of discharge, temperature, charge rate) in Wilhelm et al. 2018 match those claimed in the conclusion.  *Look in:* refs 1.  *If false:* at best the conclusion holds even if any 1 study is wrong.
4. C3: The end-of-life capacity threshold (80%) in Wilhelm et al. 2018 is consistent with the warranty conditions of commercial products.  *Look in:* refs 1.  *If false:* at best the conclusion holds even if any 1 study is wrong.
5. C4: The cycle model and calendar ageing estimates in Wilhelm et al. 2018 apply to real-world home-storage usage patterns over 20 years.  *Look in:* refs 1.  *If false:* at best the conclusion holds even if any 1 study is wrong.
6. C5: The LFP cells tested in Omar et al. 2014 are representative of those used in home-storage batteries.  *Look in:* refs 2.  *If false:* at best the conclusion holds even if any 1 study is wrong.
7. C6: The depth of discharge (80% and 20%), temperature (25°C and 40°C), and charge rates in Omar et al. 2014 are relevant to typical home-storage operation.  *Look in:* refs 2.  *If false:* at best the conclusion holds even if any 1 study is wrong.
8. U2: Laboratory results can be generalized to commercial products in real-world conditions.  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds only if every study it uses is correct.
*If all 8 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: Wilhelm et al. 2018 (ref 1)
- S2: Omar et al. 2014 (ref 2)
- S3: Pylontech EVOLVE LFP datasheet (ref 3)
- S4: GoodWe Lynx A G3 datasheet (ref 4)
- S5: Deye/SANA Energy Datasheet (ref 5)

**Smallest ways the conclusion can lose all support** (145 in total): U3 false; C10, U2 false; C11, U2 false; C7, U2 false; C8, U2 false; C9, U2 false ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2, U3; a person must accept them.
- References whose study could not be identified: none.

## fasting: Does intermittent fasting produce more weight loss than continuous calorie restriction in adults?

### anthropic/claude-haiku-4.5

**Conclusion.** Intermittent fasting does not consistently produce more weight loss than continuous calorie restriction in adults, and when energy intake is comparable, both approaches generally yield similar weight loss, although alternate-day fasting may provide a small additional short-term advantage.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 4 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 4 studies are wrong.

**Checklist to reach the target** (4 checks; all must be confirmed; single points of failure first)
1. U1 [single point of failure]: Systematic reviews and meta-analyses of RCTs provide valid evidence for drawing conclusions about the comparative effectiveness of weight loss interventions  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
2. C1: The trials included in the systematic reviews are representative of real-world weight loss outcomes in adults  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* at best the conclusion holds only if every study it uses is correct.
3. C2: The modest differences in weight loss (0.94-1.29 kg) reported are clinically meaningful or not meaningful as intended by the conclusion  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
4. C3: Short-term advantages (3-6 months) do not translate to long-term superiority of intermittent fasting  *Look in:* refs 3, 5.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
*If all 4 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: Yu et al. 2025 systematic review and network meta-analysis of 99 RCTs (ref 1)
- S2: 2024 systematic review and meta-analysis of 10 RCTs on fasting vs continuous caloric restriction (ref 2)
- S3: Allaf et al. 2021 Cochrane systematic review (ref 3)
- S4: 2018 systematic review and meta-analysis of RCTs on intermittent vs continuous energy restriction (ref 4)
- S5: 2024 network meta-analysis of 47 RCTs on caloric restriction regimens (ref 5)

**Smallest ways the conclusion can lose all support** (24 in total): U1 false; C1, C4 false; C1, C5 false; C1 false and S4 wrong; C1 false and S2 wrong; C1 false and S1 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2; a person must accept them.
- References whose study could not be identified: none.

### openai/gpt-4.1

**Conclusion.** Intermittent fasting does not consistently produce more weight loss than continuous calorie restriction in adults; when energy intake is comparable, both approaches generally yield similar weight loss, although alternate-day fasting may provide a small additional short-term advantage.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 4 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 4 studies are wrong.

**Checklist to reach the target** (5 checks; all must be confirmed; single points of failure first)
1. C1 [single point of failure]: The populations, interventions, and comparators in the cited trials are sufficiently similar to the general adult population considering weight loss strategies.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
2. C2 [single point of failure]: The durations of the trials are long enough to assess meaningful differences in weight loss between intermittent fasting and continuous calorie restriction.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
3. C3 [single point of failure]: The calorie intake in the intermittent fasting and continuous restriction arms is comparable in the relevant studies.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
4. C4 [single point of failure]: The adherence rates in the studies reflect what would be expected in real-world settings.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
5. U1 [single point of failure]: Weight loss is the primary and sufficient outcome for evaluating the superiority of one dietary strategy over another for adults.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
*If all 5 are confirmed:* the conclusion holds even if any 4 studies are wrong.

**Studies behind the references**
- S1: Yu 2025 BMJ network meta-analysis (ref 1)
- S2: Obesity 2024 systematic review and meta-analysis (ref 2)
- S3: Allaf 2021 Cochrane review (ref 3)
- S4: BMC Endocrine Disorders 2018 meta-analysis (ref 4)
- S5: Int J Behav Nutr Phys Act 2024 network meta-analysis (ref 5)

**Smallest ways the conclusion can lose all support** (6 in total): C1 false; C2 false; C3 false; C4 false; U1 false; S1, S2, S3, S4, S5 wrong

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1; a person must accept them.
- References whose study could not be identified: none.

### qwen/qwen3-235b-a22b-2507

**Conclusion.** Intermittent fasting does not consistently produce more weight loss than continuous calorie restriction in adults; when energy intake is comparable, both approaches generally yield similar weight loss, although alternate-day fasting may provide a small additional short-term advantage.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 3 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 3 studies are wrong.

**Checklist to reach the target** (5 checks; all must be confirmed; single points of failure first)
1. U1 [single point of failure]: Weight loss outcomes from clinical trials generalize to the broader adult population considering weight-loss strategies.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
2. U2 [single point of failure]: The definition of 'intermittent fasting' and 'continuous calorie restriction' is consistent across all included studies in the cited reviews.  *Look in:* refs 1, 2, 3, 4, 5.  *If false:* no support remains; stop.
3. C1: The trials in the Oi-Ying Yu et al. 2025 meta-analysis are representative of adult populations seeking weight loss and use comparable energy intake between intermittent and continuous restriction.  *Look in:* refs 1.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
4. C2: The 2024 Obesity meta-analysis includes trials where fasting and continuous restriction were matched for total caloric intake over time.  *Look in:* refs 2.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
5. U3: Short-term weight loss differences are indicative of long-term outcomes when adherence is maintained.  *Look in:* refs 2, 5.  *If false:* at best the conclusion holds even if any 1 study is wrong.
*If all 5 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: Oi-Ying Yu et al. 2025 meta-analysis (ref 1)
- S2: Obesity 2024 meta-analysis (ref 2)
- S3: Allaf et al. Cochrane 2021 review (ref 3)
- S4: BMC Endocrine Disorders 2018 meta-analysis (ref 4)
- S5: IJBNPA 2024 network meta-analysis (ref 5)

**Smallest ways the conclusion can lose all support** (42 in total): U1 false; U2 false; C1, C3, U3 false; C1, C4, U3 false; C1, U3 false and S3 wrong; C1, U3 false and S4 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2, U3; a person must accept them.
- References whose study could not be identified: none.

## heatpump: Do domestic heat pumps reduce heating-related CO2 emissions compared with gas boilers in the UK?

### anthropic/claude-haiku-4.5

**Conclusion.** Domestic heat pumps generally reduce heating-related CO₂ emissions compared with gas boilers in the UK, although the size of the reduction depends on heat-pump type, seasonal efficiency, electricity carbon intensity, refrigerant impacts, and whether manufacture and installation are included.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 3 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 3 studies are wrong.

**Checklist to reach the target** (4 checks; all must be confirmed; single points of failure first)
1. C1: The 84% emissions reduction in 2024 and comparison with 2014 applies to UK household heating contexts with current electricity grid composition  *Look in:* refs 3, 5, 6.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
2. C3: The UCL lifecycle assessment carbon intensities (0.111 kg CO₂e/kWh for air-source, 0.097 for ground-source, 0.241 for gas boiler) apply to UK conditions and current technology  *Look in:* refs 3, 5, 6.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
3. U1: The lifecycle assessment studies adequately account for all relevant emissions sources (manufacturing, installation, operation, refrigerant leakage, end-of-life) to enable valid comparison  *Look in:* refs 1, 3, 5, 6.  *If false:* at best the conclusion holds only if every study it uses is correct.
4. U2: The gas boiler baseline (200-215 g CO₂/kWh) is representative of typical UK gas boiler systems being replaced  *Look in:* refs 1, 3, 5, 6.  *If false:* at best the conclusion holds only if every study it uses is correct.
*If all 4 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: unknown (refs 1, 2, 4)
- S2: Sevindik et al. 2021 UCL lifecycle assessment (ref 3)
- S3: Sevindik et al. 2021 UCL hybrid heat pump lifecycle assessment (ref 5)
- S4: Carbon Brief 2024 UK electricity analysis (ref 6)

**Smallest ways the conclusion can lose all support** (20 in total): C1, U1 false; C1, U2 false; U1 false and S4 wrong; U2 false and S4 wrong; C1, C3, C4, C5 false; C1, C3, C4 false and ref1 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2, U3; a person must accept them.
- References whose study could not be identified: 1.

### openai/gpt-4.1

**Conclusion.** Domestic heat pumps generally reduce heating-related CO₂ emissions compared with gas boilers in the UK, although the size of the reduction depends on several factors.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 2 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 2 studies are wrong.

**Checklist to reach the target** (6 checks; all must be confirmed; single points of failure first)
1. C3 [single point of failure]: The seasonal performance factors (efficiency) of heat pumps in the studies are typical of real-world UK installations.  *Look in:* refs 1, 2, 3, 5, 6.  *If false:* no support remains; stop.
2. C5 [single point of failure]: The operational and lifecycle emissions reductions found in the cited studies are transferable to the general UK domestic context.  *Look in:* refs 1, 2, 3, 5, 6.  *If false:* no support remains; stop.
3. U1 [single point of failure]: Reducing heating-related CO₂ emissions is a desirable or relevant goal for UK domestic heating policy or consumer choice.  *Look in:* refs 1, 2, 3, 5, 6.  *If false:* no support remains; stop.
4. C1: The heat pumps and gas boilers assessed in the cited studies are representative of those currently installed in UK homes.  *Look in:* refs 1, 2, 3.  *If false:* at best the conclusion holds only if every study it uses is correct.
5. C2: The carbon intensity of UK electricity in the cited studies matches or is relevant to current and near-future UK conditions.  *Look in:* refs 1, 5, 6.  *If false:* at best the conclusion holds only if every study it uses is correct.
6. C4: The lifecycle assessments include all relevant emissions sources (operation, manufacture, refrigerants, etc.) in a comparable way for both heat pumps and gas boilers.  *Look in:* refs 1, 2, 3.  *If false:* at best the conclusion holds only if every study it uses is correct.
*If all 6 are confirmed:* the conclusion holds even if any 2 studies are wrong.

**Studies behind the references**
- S1: The Independent 2026 summary article (unknown underlying primary study) (ref 1)
- S2: Selman Sevindik et al. 2021 UCL lifecycle assessment (ref 2)
- S3: Selman Sevindik et al. 2021 UCL hybrid heat pump vs gas boiler assessment (ref 3)
- S4: Manchester Institute of Innovation Research 2026 lifecycle report (ref 4)
- S5: UK Collaborative Centre for Housing Evidence 2025 analysis (ref 5)
- S6: Carbon Brief 2025 analysis of UK electricity carbon intensity (ref 6)

**Smallest ways the conclusion can lose all support** (15 in total): C3 false; C5 false; U1 false; C1, C2 false; C1 false and S6 wrong; C1 false and S5 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1; a person must accept them.
- References whose study could not be identified: none.

### qwen/qwen3-235b-a22b-2507

**Conclusion.** Domestic heat pumps generally reduce heating-related CO₂ emissions compared with gas boilers in the UK, although the size of the reduction depends on several factors.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 3 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 3 studies are wrong.

**Checklist to reach the target** (6 checks; all must be confirmed; single points of failure first)
1. C6 [single point of failure]: The comparison between heating systems includes the same functional unit (e.g., per kWh of useful heat delivered).  *Look in:* refs 3, 5, 6, 10, 14.  *If false:* no support remains; stop.
2. C1: The seasonal coefficient of performance (SCOP) of the heat pump is sufficient to maintain low electricity consumption relative to heat output.  *Look in:* refs 3, 5, 10.  *If false:* at best the conclusion holds only if every study it uses is correct.
3. C2: The UK electricity grid carbon intensity in the time and context of the analysis matches or is similar to the values used in the cited studies (e.g., 2024 levels).  *Look in:* refs 6, 14.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
4. C5: The gas boiler being compared is a standard condensing gas boiler with typical efficiency and emissions characteristics in the UK context.  *Look in:* refs 3, 5, 6, 14.  *If false:* at best the conclusion holds only if every study it uses is correct.
5. U1: The electricity carbon intensity used in the Carbon Brief analysis (ref 14 and 6) is representative of the national average for household heating use over the year.  *Look in:* refs 6, 14.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
6. U2: The seasonal performance factor (SPF) of 3.0 mentioned in the UK housing analysis (ref 10) is achievable in real-world UK domestic settings.  *Look in:* refs 10.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
*If all 6 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: unknown (refs 1, 4, 10)
- S2: Sevindik 2021 circular economy assessment (ref 2)
- S3: Sevindik 2021 hybrid heat pump comparison (ref 3)
- S4: UK Housing Evidence Centre 2025 hybrid system LCA (ref 5)
- S5: Carbon Brief 2025 UK electricity analysis (refs 6, 14)

**Smallest ways the conclusion can lose all support** (31 in total): C6 false; C1, C2 false; C1, C5 false; C1, U1 false; C1 false and S5 wrong; C5, U2 false ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2, U3; a person must accept them.
- References whose study could not be identified: 10.

## melatonin: Does melatonin improve sleep quality in adults with chronic insomnia?

### anthropic/claude-haiku-4.5

**Conclusion.** Melatonin may produce small improvements in some sleep measures, but evidence does not establish a clinically important improvement in overall sleep quality for adults with chronic insomnia, and major guidelines therefore recommend against routine use.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 3 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 3 studies are wrong.

**Checklist to reach the target** (4 checks; all must be confirmed; single points of failure first)
1. U1 [single point of failure]: Lack of clinically important improvement in overall sleep quality is a sufficient basis for recommending against routine use of a treatment  *Look in:* refs 1, 2, 3, 4, 5, 6, 7, 8.  *If false:* no support remains; stop.
2. C3: The 2013 meta-analysis (ref 3) findings on primary sleep disorders do not represent reliable treatment effects specifically for chronic insomnia in adults  *Look in:* refs 3, 4.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
3. C4: The 2021 meta-analysis (ref 4) findings from diverse medical conditions do not represent reliable treatment effects for chronic insomnia specifically  *Look in:* refs 3, 4.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
4. C7: Major clinical guidelines (AASM, NCCIH, VA/DoD) represent current authoritative guidance on melatonin use for chronic insomnia  *Look in:* refs 7, 8.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
*If all 4 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: 2022 systematic review of 24 placebo-controlled randomized trials on melatonin for chronic insomnia (ref 1)
- S2: 2020 systematic review and network meta-analysis of pharmacological and nonpharmacological interventions for insomnia (ref 2)
- S3: Ferracioli-Oda et al. 2013 meta-analysis of melatonin for primary sleep disorders (ref 3)
- S4: 2021 systematic review and meta-analysis of melatonin supplementation on sleep quality in randomized controlled trials (ref 4)
- S5: 2022 systematic review and meta-analysis of melatonin and ramelteon for insomnia in older adults (ref 5)
- S6: American Academy of Family Physicians 2021 review of melatonin for insomnia in older adults (ref 6)
- S7: American Academy of Sleep Medicine 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia in adults (ref 7)
- S8: National Center for Complementary and Integrative Health updated resource on sleep disorders and complementary health approaches (ref 8)

**Smallest ways the conclusion can lose all support** (241 in total): U1 false; C1, C3, C5, C7 false; C1, C3, C5 false and S7 wrong; C1, C3, C5 false and S8 wrong; C1, C3, C6, C7 false; C1, C3, C6 false and S7 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2; a person must accept them.
- References whose study could not be identified: none.

### openai/gpt-4.1

**Conclusion.** Melatonin may produce small improvements in some sleep measures, but evidence does not establish a clinically important improvement in overall sleep quality for adults with chronic insomnia; major guidelines therefore recommend against routine use.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 2 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 2 studies are wrong.

**Checklist to reach the target** (5 checks; all must be confirmed; single points of failure first)
1. C1 [single point of failure]: The populations, doses, and formulations studied in the cited trials and reviews are representative of adults with chronic insomnia in general clinical practice.  *Look in:* refs 1, 2, 3, 4, 5, 6, 7, 8.  *If false:* no support remains; stop.
2. C2 [single point of failure]: The sleep quality measures used in the cited studies are valid indicators of clinically important improvement.  *Look in:* refs 1, 2, 3, 4, 5, 6, 7, 8.  *If false:* no support remains; stop.
3. C5 [single point of failure]: Improvements in sleep-onset latency or total sleep time without improvement in overall sleep quality are not clinically important for adults with chronic insomnia.  *Look in:* refs 1, 2, 3, 4, 5, 6, 7, 8.  *If false:* no support remains; stop.
4. U1 [single point of failure]: A clinically important improvement in overall sleep quality is necessary for recommending routine use of melatonin in adults with chronic insomnia.  *Look in:* refs 1, 2, 3, 4, 5, 6, 7, 8.  *If false:* no support remains; stop.
5. C3: Findings from studies including children, adolescents, older adults, or populations with diverse medical conditions do not generalize to the general adult population with chronic insomnia.  *Look in:* refs 3, 4, 5, 6.  *If false:* at best the conclusion holds only if every study it uses is correct.
*If all 5 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: 2022 systematic review and meta-analysis of melatonin for chronic insomnia (ref 1)
- S2: 2020 systematic review and network meta-analysis of insomnia interventions (ref 2)
- S3: Ferracioli-Oda 2013 meta-analysis of melatonin for primary sleep disorders (ref 3)
- S4: 2021 systematic review and meta-analysis of melatonin supplementation on sleep quality (ref 4)
- S5: 2022 systematic review and meta-analysis of melatonin/ramelteon for insomnia in older adults (ref 5)
- S6: Trials of prolonged-release melatonin in adults aged 55+ (as summarized by AAFP 2021) (ref 6)
- S7: American Academy of Sleep Medicine 2017 clinical practice guideline (ref 7)
- S8: NCCIH 2026 summary of reviews and US guidelines (ref 8)

**Smallest ways the conclusion can lose all support** (29 in total): C1 false; C2 false; C5 false; U1 false; C3, C4 false; C3 false and S2 wrong ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1; a person must accept them.
- References whose study could not be identified: none.

### qwen/qwen3-235b-a22b-2507

**Conclusion.** Melatonin may produce small improvements in some sleep measures, but evidence does not establish a clinically important improvement in overall sleep quality for adults with chronic insomnia; major guidelines therefore recommend against routine use.
**Target.** The conclusion should hold even if any 1 study is wrong (k = 2).

**Status: NOT CERTIFIED yet.**
- If every assumption below holds, the conclusion holds even if any 3 studies are wrong.
- Now: no guarantee yet, since every route still rests on an unchecked assumption.
- Best reachable by checking: the conclusion holds even if any 3 studies are wrong.

**Checklist to reach the target** (5 checks; all must be confirmed; single points of failure first)
1. C1: The populations in the studies cited (refs 1, 2, 3, 4) are representative of adults with chronic insomnia.  *Look in:* refs 1, 2, 3, 4.  *If false:* at best the conclusion holds even if any 1 study is wrong.
2. C2: The melatonin formulations and doses used in the studies (refs 1, 2, 3, 4) are comparable to those used by the general adult population (e.g., immediate-release, over-the-counter).  *Look in:* refs 1, 2, 3, 4, 5, 6.  *If false:* at best the conclusion holds only if every study it uses is correct.
3. C3: The outcome measures of sleep quality in the studies (refs 1, 2, 3, 4) align with clinically meaningful improvements in overall sleep quality.  *Look in:* refs 1, 2.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
4. C5: The positive results in populations with diverse medical conditions (ref 4) do not generalize to adults with chronic insomnia alone.  *Look in:* refs 3, 4.  *If false:* at best the conclusion holds even if any 2 studies are wrong.
5. U1: Improvements in sleep measures such as sleep-onset latency or total sleep time are not sufficient to constitute clinically important improvement in overall sleep quality.  *Look in:* refs 1, 2, 3, 4.  *If false:* at best the conclusion holds even if any 1 study is wrong.
*If all 5 are confirmed:* the conclusion holds even if any 1 study is wrong.

**Studies behind the references**
- S1: 2022 systematic review and meta-analysis of melatonin for chronic insomnia (ref 1)
- S2: 2020 systematic review and network meta-analysis of pharmacological and nonpharmacological interventions for insomnia (ref 2)
- S3: Ferracioli-Oda et al. 2013 meta-analysis of melatonin for primary sleep disorders (ref 3)
- S4: 2021 meta-analysis of melatonin supplementation on sleep quality in randomized trials (ref 4)
- S5: 2022 systematic review and meta-analysis of melatonin and ramelteon in older adults (ref 5)
- S6: American Academy of Family Physicians 2021 clinical summary on melatonin in older adults (ref 6)
- S7: American Academy of Sleep Medicine 2017 clinical practice guideline (ref 7)
- S8: National Center for Complementary and Integrative Health 2026 report on sleep disorders (ref 8)

**Smallest ways the conclusion can lose all support** (180 in total): C2, C8 false; C2, U2 false; C2 false and S7 wrong; C2 false and S8 wrong; C1, C6, C8 false; C1, C6, U2 false ...

**Not covered by this card**
- Whether each cited passage says what the report claims (citation checks are assumed done).
- Assumptions the report never states, added during reading: U1, U2; a person must accept them.
- References whose study could not be identified: none.

